Oncotarget

Priority Research Papers:

p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways

Maria Shatz, Igor Shats, Daniel Menendez and Michael A. Resnick _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:16963-16980. https://doi.org/10.18632/oncotarget.4435

Metrics: PDF 1516 views  |   HTML 1639 views  |   ?  


Abstract

Maria Shatz1, Igor Shats2, Daniel Menendez1 and Michael A. Resnick1

1 Chromosome Stability Group, Laboratory of Molecular Genetics, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, NC, USA

2 Department of Biomedical Engineering, Duke University, Durham, NC, USA

Correspondence to:

Maria Shatz, email:

Michael A. Resnick, email:

Keywords: p53, Toll-like receptor 5, cancer, signal transduction, inflammation

Received: February 06, 2015 Accepted: June 02, 2015 Published: June 10, 2015

Abstract

The p53 tumor suppressor regulates transcription of genes associated with diverse cellular functions including apoptosis, growth arrest, DNA repair and differentiation. Recently, we established that p53 can modulate expression of Toll-like receptor (TLR) innate immunity genes but the degree of cross-talk between p53 and TLR pathways remained unclear. Here, using gene expression profiling we characterize the global effect of p53 on the TLR5-mediated transcription in MCF7 cells. We found that combined activation of p53 and TLR5 pathways synergistically increases expression of over 200 genes, mostly associated with immunity and inflammation. The synergy was observed in several human cancer cells and primary lymphocytes. The p53-dependent amplification of transcriptional response to TLR5 activation required expression of NFκB subunit p65 and was mediated by several molecular mechanisms including increased phosphorylation of p38 MAP kinase, PI3K and STAT3 signaling. Additionally, p53 induction increased cytokine expression in response to TNFα, another activator of NFκB and MAP kinase pathways, suggesting a broad interaction between p53 and these signaling pathways. The expression of many synergistically induced genes is elevated in breast cancer patients responsive to chemotherapy. We suggest that p53’s capacity to enhance immune response could be exploited to increase antitumor immunity and to improve cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4435